ライフサイエンスコーパス: symptom

1 are case of KD with cholestasis as principal symptom.

2 and treatable prior to the onset of clinical symptoms.

3 mitochondrial activity, ameliorated pre-IBD symptoms.

4 ed in cases of ATL years before the onset of symptoms.

5 g medications as the indicator of persisting symptoms.

6 t true cyclodeviation and relationships with symptoms.

7 ease stage along with other neuropsychiatric symptoms.

8 garding the presence of clots and presenting symptoms.

9 CoV-2 PCR-negative patients with respiratory symptoms.

10 tures exhibit worse cognitive and behavioral symptoms.

11 ding ketamine-induced shifts in motivational symptoms.

12 l diagnosis of KD was made on her 8th day of symptoms.

13 ells in 10 of 10 COVID-19 patients with mild symptoms.

14 ipheral nerves, causing weakness and sensory symptoms.

15 s of 'Emerald' never developing red ringspot symptoms.

16 cial for individuals experiencing consistent symptoms.

17 that are strongly correlated with a patients symptoms.

18 of recurring and episodic clinical signs and symptoms.

19 of developing post-traumatic stress disorder symptoms.

20 which underlies the development of psychotic symptoms.

21 reported experiencing burnout and depressive symptoms.

22 , optimism, resilient coping, and depressive symptoms.

23 rated by cardiovascular and gastrointestinal symptoms.

24 ated with viral load was time since onset of symptoms.

25 stipation, cognition, mood, sleep) signs and symptoms.

26 determined associations with change in ADHD symptoms.

27 ingly sought natural solutions for their IBS symptoms.

28 hy (DPN) typically is accompanied by painful symptoms.

29 nd the natural history is one of fluctuating symptoms.

30 of attention deficit/hyperactivity disorder symptoms.

31 y (FEV1:FVC) less than 0.70 with respiratory symptoms.

32 ion in children aged 28-275 days at onset of symptoms.

33 treatment without gastrointestinal and joint symptoms.

34 cheduled clinical evaluation for respiratory symptoms.

35 onsiderable variation in the presentation of symptoms.

36 er patients sought treatment within 1 day of symptoms (16/80 patients [19.5%] in 2020 vs. 41/106 pati

37 besity (body mass index >30), and depressive symptoms (2-item Patient Health Questionnaire score >=2)

38 ing participants who had moderate and severe symptoms (23 to 100 points in OSDI), office workers pres

39 Nearly a third could not correctly identify symptoms (28.3%) or ways to prevent infection (30.2%).

40 s in OSDI), office workers presented dry eye symptoms 4.15 times more frequently than construction wo

41 7% had tachycardia, 80% had gastrointestinal symptoms, 60% had rash, 56% had conjunctival injection,

42 students had the highest prevalence of GORD symptoms (63% - 127/201).

43 Most adverse events resulted only in symptoms (77%) and 36% were judged to be preventable.

44 He noticed the symptoms 8 months after starting the treatment and had s

45 delayed seroma (69.2%) and without systemic symptoms (86.5%).

46 For 13 of the 20 symptoms (abnormal mole, breast lump, post-menopausal bl

47 00 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantin

48 The development of oropharyngeal symptoms after initiating should alert the treating phys

49 alf of the patients had improvement of index symptoms after receiving palliative liver RT with median

50 Complete resolution of symptoms after surgery ranged from 66% to 95.6% for offi

51 n less frequently reported lower respiratory symptoms (age <18: 21%, age 18-49: 60%, age 50+ years: 6

52 ther than stage IV; for 19 of the 20 studied symptoms (all except for neck lump), more than a third o

53 dication (ADM) response with respect to both symptom alleviation and quality of life (QoL) in major d

54 t treatment on these measures and a range of symptom and mechanism variables.

55 uality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire (sco

56 schizophrenia during remission of psychotic symptoms and 19 age- and sex-comparable control subjects

57 tional 2.64 (95% CI 1.84 to 3.44) concussion symptoms and 7.45 (95% CI 5.22 to 9.68) higher vision sy

58 creases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of alcohol cr

59 for non-pharmacologic approaches to managing symptoms and asthma-related coughing may identify uncont

60 suggested that the association between PTSD symptoms and attachment style is bidirectional.

61 association between care partner depressive symptoms and care partner physical (B=0.05, P<0.001) and

62 hat relate more directly to the pathological symptoms and clinical parameters observed in patients.

63 e liability and induced relief of withdrawal symptoms and drug cravings, despite acting on the same o

64 Patients with mast cell (MC) activation symptoms and elevated baseline serum tryptase level (MCA

65 ers including patients' presenting signs and symptoms and granular measures of comorbidities and seve

66 those who developed ME/CFS had more physical symptoms and immune irregularities, but not more psychol

67 s tend to be reserved for people with severe symptoms and include central neuromodulators, intestinal

68 tion between allergen and rhinovirus-induced symptoms and inflammation over time is unclear.

69 g devices and experiences of musculoskeletal symptoms and injury were not significantly different by

70 between classroom NO(2) exposure and asthma symptoms and morbidity by body mass index (BMI) category

71 d information about self-reported depressive symptoms and no CVD history at baseline.

72 Worse ocular symptoms and ocular staining were also found in low-deli

73 (MCs) in various tissues, leading to severe symptoms and organ damage (eg, cytopenias, liver dysfunc

74 aps (number of errors on 7 facts on COVID-19 symptoms and prevention) and information-seeking behavio

75 roduction, and resulted in decreased disease symptoms and reduced fungal biomass in the host banana p

76 rly COPD more often have chronic respiratory symptoms and severe lung function impairment, and an inc

77 ogram included home spirometry, reporting of symptoms and side effects, patient-reported outcomes, in

78 19 typically includes survey questions about symptoms and travel history, as well as temperature meas

79 ath; (2) rehospitalization for heart failure symptoms and valve prosthesis complication; or (3) strok

80 vided rapid and sustained improvements in AD symptoms and was well tolerated.

81 t style may moderate polygenic risk for PTSD symptoms, and a novel locus implicated in synaptic trans

82 deaths presented with neurological signs and symptoms, and CHIKV-RNA was found in the CSF of 92.3% of

83 abolites, clinical response, psychotomimetic symptoms, and gamma power changes in 34 individuals (age

84 and monitored for infection, gastroenteritis symptoms, and immune responses.

85 e predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.

86 tinal symptoms, non-gastrointestinal somatic symptoms, and psychological dysfunction.

87 differences in pain sensitivity, depressive symptoms, and reward processing.

88 ) and a broad range of childhood psychiatric symptoms, and to quantify the extent to which such assoc

89 affiliation with others experiencing similar symptoms; and adaptive emotion regulation strategies amo

90 alabsorption and subsequent gastrointestinal symptoms are a common clinical problem in pediatrics.

91 These dopamine (DA) replacement-resistant symptoms are associated with losses of basal forebrain a

92 However, the initial motor symptoms are usually very subtle and, as a result, patie

93 ort further evaluation of alcohol withdrawal symptoms as a prognostic indicator of prazosin's efficac

94 d analyzed with maternal prenatal depressive symptoms as well as child behavior.

95 Subjective symptom assessments were estimated lowlier than objectiv

96 may help to explain some of the more complex symptoms associated with parietal damage, such as constr

97 a behavioral phenotype that mimics multiple symptoms associated with schizophrenia.

98 sion, generalized anxiety, and hyperactivity symptoms at age 19.

99 ersus euthyroidism, adjusting for depressive symptoms at baseline, age, sex, education, and income (P

100 The most common symptoms at PIIRS diagnosis were altered mental status a

101 ition, major depressive disorder, depressive symptoms, autism spectrum disorder, psychosis, and alcoh

102 Given that symptom-based classification approaches do not align wit

103 Symptom-based criteria are used to make a diagnosis, wit

104 biome vs control individuals, independent of symptom-based subtypes of IBS.

105 es endure immense physical and psychological symptoms because of both their illness and often intensi

106 rajectories of children's anxiety-depression symptoms between ages 3 to 8 years (adjusted odds ratio,

107 tage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL),

108 ess acute health care use and modestly lower symptom burden, but there was no significant difference

109 human vaccines are leaky because they block symptoms but do not prevent infection or onward transmis

110 ing dietary intervention for alleviating T2D symptoms, but its protective effect on diabetes-driven c

111 endometriosis that manifest with nonspecific symptoms, but their detection involves specific therapeu

112 lth care use; for some, fibromyalgia and its symptoms can be debilitating.

113 The mechanism underlying these symptoms can be explained by the presence of nonfiring p

114 ominal pain, weight loss, and the "any other symptom" category), more than 50% of patients were diagn

115 diomyopathy as clinically the most prevalent symptom caused by biallelic mutations within the leucine

116 ere used to quantify relative variability in symptom change.

117 h the Pittsburgh Sleep Quality Index (PSQI), Symptom Checklist 90 (SCL-90), Hamilton Anxiety Scale (H

118 Little is known about the changes in symptom classification over time in patients with periph

119 ry disease and the association of changes in symptom classification with subsequent cardiovascular di

120 patients (7%) had new transient or permanent symptoms classified by the CTCAE.

121 These symptoms cleared completely after the drug was discontin

122 mutation carriers exhibited neuropsychiatric symptoms compared with non-carriers that may be consider

123 ted 2012 to 2016 for SAVR, TAVR, and disease symptoms (congestive heart failure, unstable angina, non

124 5.1% of patients had one or more visits with symptoms consistent with CM, and during those visits, 71

125 Early drug generations focused largely on symptom control and pain management, effective targets f

126 The strongest neurophysiology-symptom correlations occurred between a combination of C

127 lp-seeking samples based only on more severe symptom cutoff thresholds will likely have little impact

128 lizing, collecting, and analyzing concussion symptom data.

129 hy persons more susceptible to dry eye (DED) symptoms developing after surgery remains an unmet need.

130 decline occurs in HLB-affected trees before symptom development among leaves.

131 nimal model and was related to reducing PTSD symptom development in humans.

132 role of phytohormones in BS induction and BS symptom development.

133 al SCFA concentration, gastrointestinal (GI) symptoms, dietary intake, and quality of life were measu

134 drug reaction with eosinophilia and systemic symptoms (DiHS/DRESS) is a potentially fatal multiorgan

135 Cohort Study completed surveys assessing 10 symptom domains and SF-36 HRQOL summary scores.

136 ortened shedding and significantly shortened symptom duration (influenza-like illness, 82%; 95% CI, 3

137 ients with comorbidities and longer previous symptom duration recovered 2-3 days sooner.

138 at baseline in 120 (60%); 20 (10%) developed symptoms during follow-up of 2.8 +/- 3.0 years.

139 nson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Le

140 follow individuals as subthreshold psychotic symptoms emerge.

141 ore was calculated for each subject based on symptoms experienced during peanut challenge and the eli

142 ased on the report of persistent, subjective symptoms for >= 6 months following antibiotic treatment

143 indices integrating the most common initial symptoms for each genetic group.

144 Dosing symptom frequency in participants who are BE-tolerant wa

145 idered diagnostic of gastroesophageal reflux symptoms (GERD).

146 AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25 mug/L (AUC

147 Participants reporting urogenital symptoms had a significantly elevated risk of M. genital

148 eeding, rectal bleeding, lower urinary tract symptoms, haematuria, change in bowel habit, hoarseness,

149 arly in youth with persistent psychosis risk symptoms, however, there is little evidence to suggest t

150 HAdV infections typically cause mild symptoms; however, individuals such as children, those w

151 ARI, compared with those without respiratory symptoms (ie, asymptomatic individuals) or healthy older

152 E-HF study (Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During En

153 The maps predicted symptom improvement in an exploratory analysis of stimul

154 se circuit maps were reproducible, predicted symptom improvement in independent patient cohorts, and

155 o sensory input is a common and debilitating symptom in individuals with autism spectrum disorders (A

156 l somatostatin interneurons alleviates motor symptoms in a parkinsonian mouse model.

157 of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer's disease', by Tetreault etal.

158 ant to help understand changing or worsening symptoms in an individual.

159 ed flexible behavior in relation to clinical symptoms in ASD.

160 tribute to subsequent anxiety and depression symptoms in childhood.

161 Elevated anxiety symptoms in combination with high-risk biological factor

162 ent within 8 hours after the onset of stroke symptoms in conjunction with standard care resulted in b

163 mputed data, less interference of neurologic symptoms in daily activities (P = .008) and fewer cognit

164 Dolorimetry correlated with symptoms in GWI but not CFS or FM.

165 to be used to treat depression and psychotic symptoms in HD.

166 compare the frequency of COVID-19 associated symptoms in participants with and without SARS-CoV-2 ant

167 borns of infected mothers can display severe symptoms, including neurodevelopmental abnormalities and

168 childhood predicting the persistence of ADHD symptoms into adulthood, the genetic architecture underl

169 n the ICS dose alone for worsening of asthma symptoms is not recommended.

170 mental feature of the human brain and drives symptom lateralization in Parkinson's disease (PD), but

171 ently asymptomatic (39%) and had respiratory symptoms less often than younger children (29% vs. 48%;

172 The primary symptoms linked to deployment are posttraumatic stress d

173 pecimens from 251 participants with COVID-19 symptoms (<=7 days from symptom onset [DSO], >=18 years

174 regularly perform LS report musculoskeletal symptoms, mainly in neck and shoulders.

175 d goals, with a focus on quality of life and symptom management.

176 associated with neuroimaging, cognition, and symptom measures.

177 Two symptom-medication scores were used: the modified EAACI

178 The pathophysiology of visual symptoms might involve dysfunctional visual cortex.

179 culation, Deltawak1 plants developed disease symptoms more slowly than Deltafls2.1/2.2/3 mutant plant

180 that psychological interventions reduce PTSD symptoms more than inactive control (k = 46; n = 3,389;

181 Symptom network analysis was conducted to evaluate netwo

182 About half of the participants had symptom networks that were sparse after controlling for

183 ps between nausea and other gastrointestinal symptoms, non-gastrointestinal somatic symptoms, and psy

184 presentation of fevers, rashes, and mucosal symptoms observed in many of these syndromes, patients a

185 s surveyed were experiencing at least one GI symptom of a severity greater than normative levels.

186 athy, but not depression, may be a prodromal symptom of dementia in SVD, and may be useful in identif

187 neurons, and shows that Hick's law may be a symptom of near-optimal parallel decision-making with no

188 ase (IBD) that may be marked by debilitating symptoms of abdominal pain and obstruction.

189 ield of view (FOV) act as a mediator between symptoms of attention deficit hyperactivity disorder (AD

190 3 activity might open new ways to understand symptoms of Best vitelliform macular dystrophy such as r

191 n should monitor such patients for signs and symptoms of cannabis use disorder.

192 be used in patients with moderate to severe symptoms of COVID-19.

193 Worse symptoms of DED are associated with decreased work produ

194 ty with the Patient Health Questionnaire for symptoms of depression and anxiety.

195 were monitored every 6 months for signs and symptoms of diarrheal disease, acute respiratory illness

196 e consequences in controlling the spread and symptoms of disease.

197 tudy was to investigate associations between symptoms of gastroenteritis and the presence of airborne

198 neurons is presumed to underlie most of the symptoms of MCHS.

199 line survey, postdisaster social capital and symptoms of mental disorders were measured using the Scr

200 (mOR, 3.7 [95% CI, 1.0-12.6]; P = .045), and symptoms of mental illness (mOR, 2.6 [95% CI, 1.2-5.5];

201 There was no evidence of shifts in symptoms of mild or severe depression.

202 d tolerability of pitolisant in treating the symptoms of narcolepsy.

203 l trial of rilonacept in patients with acute symptoms of recurrent pericarditis (as assessed on a pat

204 The emergence of prodromal symptoms of schizophrenia and their evolution into overt

205 Given the nonspecific symptoms of these disorders, a high index of suspicion i

206 nd decipher the contribution of genes to the symptoms of TS and KOS.

207 ted values), clinical malaria (infection and symptoms on the basis of study-specific definitions) dur

208 The most commonly reported symptoms on the day of first positive RT-PCR test were u

209 ts had abnormal MRI findings 2-4 weeks after symptom onset (58.9%), including 17 with acute ischemic

210 ipants with COVID-19 symptoms (<=7 days from symptom onset [DSO], >=18 years of age) were utilized to

211 roup analysis, treatment within 7 days after symptom onset led to lower 90-day mortality than use of

212 A delay from symptom onset to first injection of 30 days or more pred

213 Self-isolation by 20% of cases 24 h after symptom onset would delay and flatten the outbreak traje

214 the upper airway prior to or at the time of symptom onset, an unusual feature that has enabled wides

215 tandem with immunoglobulin titers following symptom onset, and positive percent agreement between de

216 sitivity to >80% between days 6 and 10 after symptom onset.

217 % CI, 85.0%-98.3%) for samples >14 days post symptom onset.

218 oV-2-specific serum IgA and IgG titers after symptom onset.

219 age diagnostic delay is up to 5-6 years from symptom onset.

220 g severity who presented within a week after symptom onset.

221 infection, lower propensity to show clinical symptoms or both.

222 protocols and in populations with resistant symptoms or intolerance to analgesic medications.

223 ted individuals, who can either exhibit mild symptoms or progress toward a life-threatening acute res

224 Relapse was defined as new or reappearing symptoms or worsening disease, with a Birmingham Vasculi

225 was associated with increased likelihood of symptoms (OR: 3.91, 95%CI: 1.55-9.87).

226 fferences between different participants and symptoms, our multi-task learning models perform statist

227 ts who tested negative on 15 March developed symptoms over follow-up; of these, 3 were re-tested and

228 ly activities (P = .008) and fewer cognitive symptoms (P = .01).

229 was from the genetic loading for depressive symptoms (p = 0.001, standardized coefficient beta = - 3

230 Symptom patterns differed significantly between constipa

231 For many patients, these symptoms persist for years and lead to frequent health c

232 Symptoms, pre-/post-bronchodilator lung function, atopy,

233 PP) and 32 healthy controls (HC) underwent a symptom provocation paradigm during which subjects watch

234 derwent baseline and postprandial MRI scans, symptom questionnaires, and blood sampling following a 4

235 gue infection induces a spectrum of clinical symptoms, ranging from classical dengue fever to severe

236 r time, which leads to treatment failure and symptom recurrence.

237 onnectivity were associated with larger PTSD symptom reductions.

238 tion carriers demonstrate unique FTD-related symptoms relative to familial mutation non-carriers.

239 However, the neural elements mediating symptom relief are unclear.

240 Children infected with GII.4 had more severe symptoms requiring more medical care.

241 flow rate (MFR), and International Prostate Symptom Score (IPSS); sexual function was assessed by 5-

242 re was no evidence that baseline Hypothyroid Symptoms score or Tiredness score modified the effects o

243 r accounting for baseline dissimilarities in symptom scores (all p(interaction) >0.05).

244 Secondary outcomes - clinical symptom scores at 2, 3, and 5 years.

245 edicated Atypical MPDs had no differences in symptom scores.

246 Most participants (94%) had a positive WHO symptom screen for TB on enrollment, and 45% were diagno

247 Compared with milder symptoms, severe IBS-D was associated with increased med

248 ed bacterial profile was associated with IBS symptom severity and breath tests results at baseline (H

249 modally distributed over a broad range, with symptom severity correlating directly with virus-specifi

250 to be symptomatic at baseline with a greater symptom severity score, but this was not found at >=6 mo

251 and 7.45 (95% CI 5.22 to 9.68) higher vision symptom severity scores throughout recovery versus those

252 Medicated Archetypal MPDs had lower symptom severity than their unmedicated counterparts; wh

253 Symptom severity was assessed using the PANSS scale.

254 on with childhood trauma in predicting worse symptom severity.

255 ere followed up by questionnaires on urinary symptoms, sexual function and impact on quality of life,

256 h-care teams, prompt diagnosis of suspicious symptoms) should be strictly followed in patients underg

257 sease (iMCD), consists of a constellation of symptoms/signs including thrombocytopenia, anasarca, fev

258 sorder (PMDD) affects over 5% of women, with symptoms similar to anxiety and major depression, and is

259 Measures of depressive symptoms, sleep quality, processing speed, and general c

260 d the average treatment effect on depressive symptoms (SMD = 0.20, 95% CI: 0.06-0.35), but more stron

261 ons of COVID-19 are dominated by respiratory symptoms, some patients present other severe damage such

262 will also localize to syndrome-specific and symptom-specific brain networks.

263 " to localize single-subject atrophy maps to symptom-specific brain networks.

264 omposition among patients with different IBS symptom subtypes.

265 characterized by common, clinically variable symptoms, such as typical facial dysmorphisms, short sta

266 e irregularities, but not more psychological symptoms, than those who recovered.

267 This is readily evident in the neurological symptoms that accompany systemic acid/base imbalances.

268 At quarterly study visits, symptoms that developed since acute EVD were recorded an

269 gLON5 disease, sleep disorders were the core symptoms that led to the description of this disease, wh

270 many patients with heart failure experience symptoms that negatively impact Quality of Life.

271 Given the heterogeneity in symptoms, the detection of clinical transition to sympto

272 fects of a low FODMAP diet on persistent gut symptoms, the intestinal microbiome, and circulating mar

273 After adjusting for depression symptoms, the PTSD findings in left and right LOFG remai

274 ze clinical, cognitive, and neuropsychiatric symptoms to brain networks, providing insight into brain

275 Biomarkers or specific clinical symptoms to identify PTLDS patients do not currently exi

276 re was no evidence that concussion or vision symptom trajectories varied over time between those with

277 learning for predicting patients' individual symptom trajectories, such as feeling depressed, social,

278 uded patient characteristics, comorbidities, symptom type and duration, oxygen saturation, and labora

279 for the presence of cognitive and behavioral symptoms using a battery of neuropsychologic tests and t

280 the likelihood of each item triggering their symptoms using a five-point Likert scale (strongly disag

281 ng the Decisional Conflict Scale, depressive symptoms using the Patient Health Questionnaire-2, and s

282 tices) and individual-level (perceptions and symptoms) variables.

283 of patients with postsurgical ocular surface symptoms was 17%.

284 The median time to alleviation of symptoms was 79.0 hours for the oseltamivir arm and 84.0

285 Cases without respiratory symptoms were analyzed to calculate the proportion of di

286 Clinical symptoms were assessed retrospectively and compared with

287 stics and self-reported acute and persistent symptoms were assessed using a standardized detailed que

288 Only sickness symptoms were evident in immunodeficient mice infected w

289 The most common presenting symptoms were fever (49%) and cough (39%); initial radio

290 The most common presenting symptoms were flashes and floaters (42.5%; n = 420), dec

291 Symptoms were present at baseline in 120 (60%); 20 (10%)

292 uals required hospitalization and presenting symptoms were similar to those of nontransplant individu

293 ultation during which their COVID-19-related symptoms were verified and a lateral flow immunoassay te

294 with medication-resistant tremor, worsening symptoms when the medication wears off, and dyskinesias.

295 Beyond the symptoms which characterize their diagnoses, individuals

296 Adults develop respiratory symptoms, which can progress to acute respiratory distre

297 that eplerenone reduces congestive signs and symptoms, which enables clinicians to reduce loop diuret

298 Fever and cough are the dominant symptoms with 15% of patients developing severe illness

299 iagnosed comorbid conditions, and documented symptoms with testing positive for SARS-CoV-2.

300 sisted mainly of acute reactions (defined as symptoms within 3 days of administration of infusion; 87